Pattern of CD4 Count and Hematological Indices in HIV Serodiscordant Partners in Jos North Local Government Area of Plateau State, Nigeria

Duru Boniface Nnamdi a*, Meludu Samuel Chukwuemeka b,c, Ogbona Emmanuel Chukwuemeka c, Onah Christian Eijke c, Onyema-iloh Obiageli Bridget d and Amaifeobu Clement c

a Department of Chemical Pathology, Federal College of Veterinary and Medical Laboratory Technology, Vom, Nigeria.

b Department of Human Biochemistry, Faculty of Basic Medical Sciences, Nnamdi Azikiwe University, Awka, Nigeria.

c Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, Nnamdi Azikiwe University, Awka, Nigeria.

d Department of Chemical Pathology, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria.

Authors’ contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

ABSTRACT

This was a cross sectional study designed to evaluate the cluster of differentiation 4 (CD4) count and hematological indices in HIV serodiscordant partners in Jos, Nigeria. A total of 20 Serodiscordant HIV couples (40 patients) and 20 non HIV couples (40 controls) aged between 18 and 49 years were included in the study. Each participant provided a 5ml venous blood sample that was collected into EDTA containers for the analysis of the CD4 count and hematological indices. The following blood parameters were measured using a three pack full blood count autoanalyzer: white blood cell (WBC), red blood cell (RBC), hematocrit/packed cell volume (HCT/PCV), hemoglobin (HB), platelet count (PLT), lymphocyte, neutrophil, and mixed cell (NUE/NAC) count. The CD4+ T cell was measured using flow cytometry. The results showed that the mean RBC count, platelet count, mixed cell count (Nue/Nac), HCT/PCV and HB levels, as well
as the CD4-T cell count, were all significantly lower while the mean age was higher in the HIV serodiscordant test group compared to control group (p<0.05) respectively. The mean neutrophil, lymphocyte, and WBC counts in the HIV serodiscordant test group did not statistically differ from those in the control group (p>0.05). The HB, HCT/PCV, RBC, lymphocyte, and CD4 counts in the female HIV serodiscordant test group were statistically significantly lower than those in the female control group (p-value=0.008; 0.002; 0.000, 0.008, 0.000), respectively. The male HIV serodiscordant test group had statistically significantly lower mean neutrophil and CD4 counts than in the male control (p-value=0.000; 0.012) respectively. The female HIV seropositives had a statistically significantly lower mean RBC count, Hb, PCV, and CD4 count (p-value =0.000; 0.037, 0.005 and 0.000) than in female control respectively. Also, the female HIV exposed seronegatives had statistically significantly lower mean CD4 count (p-value =0.000) and Hb (p-value =0.037) levels than in female control while the male HIV seropositives had statistically significantly lower CD4 count compared to male control (p-value =0.000). This study has revealed significant changes in CD4-T cell count and hematological indices in HIV serodiscordant couples, which calls for an urgent interventional strategy to prevent the potential anemia, leucocytopenia, and weakened immunity that may result in both HIV seropositives and seronegative exposed couples.

Keywords: Age; anemia; CD4-T cell; serodiscordant couple/partner; hematological indices; HIV; leucocytopenia.

1. INTRODUCTION

Human immunodeficiency virus (HIV), a member of the lentivirus family, causes a range of symptoms anchored on the reduced immune function of its host by causing devastating effects on the host's innate immune capabilities, allowing HIV replication in the host cell, leading to HIV infecting new immune cells, and resulting in the host's susceptibility to infections and if unchecked, this leads to Acquired Immunodeficiency Syndrome (AIDS) [1,2]. HIV is a public health issue affecting the world's population; 79.3 million people have been infected with the virus since the epidemic began, 36.3 million have died from AIDS, and recently 37.7 million people were infected with HIV in 2020 [3]. It is the main cause of morbidity and mortality in Sub-Saharan Africa (SSA), accounting for 71% of the global population of people living with HIV [4,5]. In Nigeria, the first HIV/AIDS patient was identified and reported in Lagos in 1985 [6]. Nigeria, the most populous country in Africa [7], has 1.9 million people living with HIV (with prevalence of 1.4%) between 15–49 years, making it the third highest in HIV load [2].

HIV discordance is a situation that occurs when one partner is HIV positive and the other is HIV negative [8]. HIV serodiscordant couples are a high-risk group for HIV transmission [9]. In Sub-Saharan Africa, 50% of people living with HIV (PLWH) are in sero-discordant partnerships [10,11]. Sero-discordant married or cohabiting couples account for a large proportion of new HIV infections in Sub-Saharan Africa, and transmission within this crucial population is a preventable driver of the epidemic [12,13]. Thus, HIV preventive and treatment efforts focus on sero-discordant couples.

HIV causes AIDS, a systemic disease marked by impaired cellular and humoral immune responses [14,15] which has been linked with hematological abnormalities. Hematological abnormalities are linked to disease progression and death in HIV patients [16]. Anemia, leucopenia, neutropenia, lymphopenia, and thrombocytopenia have been observed in HIV-infected people before or after antiretroviral therapy (ART) initiation [17,16], indicating that hematological abnormalities in HIV individuals are induced by either the virus or ART. More so, anemia, lymphocyte count, and thrombocytopenia are associated with cluster of differentiation -4 (CD4) levels [17]. In addition, hematopoietic progenitor cells express CD4 receptors, type 4 C-X-C chemokine receptors and type 5 chemokine receptors, making them susceptible to being infected by HIV [18]. In light of the above, it is important to evaluate the CD4 count and hematological indices in HIV serodiscordant partners in Jos, Nigeria. Hematological indices offer physiological insights on the reticuloendothelial system and the blood picture [19], and this has not been investigated in this group before.

2. MATERIALS AND METHODS

2.1 Study Area and Location

The study area for this work was Jos North Local Government Area of Plateau State and location
includes APIN (Aids Preventive Initiative of Nigeria) section of Our Lady of Apostles (OLA) Hospital, Faith Alive Foundation Hospital and Plateau State Specialist Hospital where HIV screenings were carried out.

2.2 Study Design and Subject Selection

This study adopted a cross sectional study design approach. The participants were partners who were known to be HIV positive and exposed seronegatives and are between the ages of 18 and 49 years old. Additionally, HIV-negative couples within the aforementioned age range that appeared to be in good health were employed as controls. The HIV-positive people were already taking medication, but their negative counterparts in a serodiscordant relationship were not on ART.

2.3 Sample Size and Sampling Technique

Participants in the present study were randomly selected. The sample size required to answer the set objective at 95% confidence level in this study was calculated from the formula by Lu-Ann et al. [20].

\[ N = \frac{Z^2P(1-P)}{d^2} \]

Where:

\( N \) = The desired sample size
\( Z \) = The standard normal deviation corresponding to 95% level of confidence
\( P \) = Prevalence (Previous studies show a prevalence rate of 2.3 percent for HIV in Jos NACA, 2012)
\( d^2 \) = Degree of prevalence

Sample size = \((1.96)^2 \times 0.023 \times (1-0.023)/ (0.05)^2\)

\[ N = 3.8416 \times 0.023 \times 0.977/0.0025 \]

\[ N = 34.52 \]

10% of error made up \(10/100 \times 34.52 = 3.45\)

\[ 34.52 + 3.45 = 37.97 \]

\[ N = 38 \text{ samples} \]

This was thereafter rounded up to make 20 HIV exposed negatives and 20 HIV positives and 20 non HIV couples (40 control).

2.4 Study Population

The study population included male and female subjects in serodiscordant relationship within the age of 18 to 49 years attending the APIN section of Our Lady of Apostles Hospital, Faith Alive Foundation and Plateau State Specialist Hospital. A total of 20 serodiscordant HIV couples (40 patients) and 20 controls (40 non HIV couples) were included in the study.

2.5 Inclusion Criteria

Participants that tested HIV-negative and had been in a stable, serodiscordant relationship for at least three months were included. The study comprised participants that were registered patients at the hospitals where the study was carried out, between the ages of 18 and 49, and had the necessary status documentation. Additionally, a control group of people that were within the age bracket and appeared healthy was included in the study (non HIV subjects).

2.6 Exclusion Criteria

Participants that were already bedridden due to AIDS, those that were not registered patients or had improper documentation with the institutions were the research was carried out, and those that refused to give informed consent were all excluded from the study.

2.7 Sample Collection and Laboratory Methods

Each participant gave venous blood sample of 5 ml, which was then drawn into EDTA containers after the collection site had been cleaned with 70% alcohol. This was utilized for the determination of full blood count as well as CD4 count. Full blood count was determined using a three pack automated full blood count analyzer while the CD4 count was assayed using Flow cytometry.

2.8 Statistical Analysis

The data obtained were analyzed using independent t-test and one-way analysis of variance (ANOVA) with the aid of SPSS statistics tool version 23.0 software. Significant level was assumed at \(P<0.05\).
3. RESULTS

When compared to the control group, the HIV serodiscordant test group's mean age was statistically significantly higher (P-value = 0.000). However, when compared to the control group, the mean RBC count, platelet count, mixed cell count (Nue/Nac), HCT/PCV and HB levels, as well as the CD4-T cell count, were all statistically significantly lower in the HIV serodiscordant test group (P<0.05). However, there was no statistically significant difference (P>0.05) between the mean WBC, lymphocyte, or neutrophil counts and the control group (Table 1).

The male control group's mean age was statistically significantly higher than that of the female control group (P-value = 0.000). The female test group's mean age was statistically significantly higher than that of the female control group (P-value = 0.000). Additionally, the mean age of the male test group was a statistically significantly higher than that of the female control group and the female test group who tested positive for HIV (P-value = 0.000) respectively (Table 2).

In comparison to the control groups, as well as between the male and female test groups, there was no statistically significant difference (P-value = 0.524) in the mean level of total WBC (Table 2).

In comparison to the values seen in the female and male control groups, respectively, the mean level of RBC seen in the female test group was statistically significantly lower (P-value = 0.000). Additionally, the mean RBC level was statistically significantly lower in the male test group than in the female control group (P-value = 0.000) (Table 2).

In comparison to the female (12.95±0.98) and male (12.81±1.22) control groups, the mean HB level was statistically significantly lower in the female test group (11.48±1.43) (P-value = 0.008). There was significantly lower HCT/PCV level observed in the female test group (34.90±3.82) when compared to the female (41.00±2.90) and male (39.80±3.30) control groups (P-value = 0.002). Also, the mean HCT/PCV level was statistically significantly lower in the male test group than in female control group (35.98±9.40 Vs 41.00±2.90; P-value = 0.002).

There was statistically significantly lower platelet count observed in the male test group when compared to the female control groups (220.70±70.99 Vs 280.20±60.41; P-value = 0.022) (Table 2).

The mean NUE/NAC levels did not differ statistically significantly (P>0.05) between the test groups of males and females as well as the controls (Table 2).

The mean lymphocyte counts were statistically significantly higher in the male test group than in the female test group (52.85±8.41 Vs 44.85±11.16; P-value = 0.008), but significantly lower in the female test group compared to the male (52.00±1.86) and male (52.30±4.23) control groups (Table 2).

The mean neutrophil counts in the male test group were significantly lower than those in the female control group (34.50±8.66 Vs 40.90±6.84; P-value = 0.012), but they were not statistically different from those obtained in the female test group (Table 2).

Compared to the values seen in the male and female control groups, the mean CD4 count was statistically significantly (P-value = 0.000) lower in the female and male test groups respectively. Additionally, there was a statistically significant difference (P-value = 0.000) between the mean CD4 count in the male and female test groups (Table 2).

There were statistically significant differences when the mean ages of the study participants were compared between the groups (F-value = 15.054; P-value = 0.000). Male controls, females with HIV, and males with HIV all had mean ages that were statistically different (P-value = 0.000) from those of the participants who were female controls respectively. Additionally, the mean age of the male HIV exposed seronegative participants was statistically significantly higher than that of female controls and HIV positive individuals (P-value = 0.000, respectively) (Table 3).

The mean total white blood count (WBC), platelet count, and NUE/NAC levels did not statistically significantly differ (P>0.05) across the study groups when compared (Table 3). The mean red blood cell count was significantly different between the groups (F=5.709; P=0.000) and statistically significantly lower in the female HIV seropositives than in the male and female control groups (P=0.000), respectively (Table 3).
There was a statistically significant difference (F=2.523; P=0.000) between the groups' mean hemoglobin (HB) levels (Table 3).

There were statistically significant differences (F=3.726; P=0.005) between the male HIV exposed and seronegative groups as well as between the female HIV positive and female control groups when participants' mean levels of haematocrit/packed cell volume were compared across the study groups (Table 3).

The mean lymphocyte level differed between the study groups in a statistically significant (F=2.456; P=0.041) manner (Table 3). Additional statistically significant differences (F=2.423; P=0.043) were seen between the study groups when the neutrophil counts were compared. Additionally, compared to female HIV positives, male HIV exposed seronegatives exhibited statistically significantly (P=0.043) lower mean neutrophil counts (Table 3).

There were statistically significant differences between the research groups' mean CD4 counts (F=16.6672; P=0.000). The mean CD4 count was statistically significant (P=0.000, respectively) lower in the female HIV seropositives, female exposed HIV seronegatives, and male HIV seropositives compared to the values observed in the male and female control groups (Table 3). In comparison to female HIV positives, male HIV exposed seronegatives had a statistically significantly (P=0.000) lower mean CD4 count (Table 3).

4. DISCUSSION

Hematological abnormalities of the major blood cell lines are frequently reported by people with HIV-1 infection, including those who are not taking antiretroviral treatment and those with the disease in its severe stages [21]. Due to its damaging effects on the immune system and many human organs, which cause significant unfavorable changes in a number of hematological indices, HIV continues to be a subject of intense health relevance and discussion throughout the world.

In the current study, the mean age was statistically significantly higher in the HIV serodiscordant test group (40.5±6.1) than in the control group (35.6±6.9). Given that the mean age of HIV-positive people fall within the age range of the working class in Nigeria [22], proper and prompt therapeutic management of these people will further increase their productivity throughout the economic cycle.

The lower levels of red blood cell count, packed cell volume and hemoglobin level recorded in this study shows that the HIV serodiscordant couples are at risk of anemia. Anemia among people living with HIV (PLWH) is caused by numerous factors. Red blood cell breakdown (hemolysis) and inefficient red blood cell formation, which are influenced by infections of the spleen or circulatory system, are two ways that immune dysregulation during HIV infection can raise the risk of anemia [23]. Blood loss is a typical occurrence in PLWH and can be brought on by gastrointestinal lesions that go along with opportunistic infections or neoplastic illness. Iron, folate, or vitamin B12 deficiencies are additional pathways for HIV-related anemia [23]. Previous studies have also reported similar findings to the present study [24,1].

Table 1. CD4 count and levels of Hematological indices in the HIV serodiscordant and control groups studied (Mean±SD)

| Parameter                  | Control group (n=40) | HIV discordant test group (n=40) | t-value | P-value |
|----------------------------|---------------------|----------------------------------|---------|---------|
| Age (year)                 | 35.6±6.9            | 40.5±6.1                         | 3.350   | 0.000*  |
| WBC (cells/µL)             | 5610.0±1401.43      | 5220.0±1502.85                   | 1.200   | 0.234   |
| RBC (pg/L)                 | 4.6±0.43            | 4.1±0.54                         | 4.879   | 0.000*  |
| HB (g/dl)                  | 12.8±1.10           | 11.9±1.76                        | 2.923   | 0.005*  |
| HCT/PCV (%)                | 40.4±3.13           | 35.4±7.10                        | 4.041   | 0.000*  |
| Platelet (cells/µL)        | 277.9±56.29         | 241.2±75.48                      | 2.486   | 0.016*  |
| NUE/NAC (mixed cells (%))  | 7.4±1.68            | 6.6±1.17                         | 2.322   | 0.023*  |
| Lymphocyte (%)             | 52.1±6.17           | 48.8±10.56                       | 1.706   | 0.092   |
| Neutrophil (%)             | 40.4±5.46           | 38.2±9.71                        | 1.277   | 0.205   |
| CD4 (cells/mm³)            | 1035.20±141.11      | 616.48±348.28                    | 7.047   | 0.000*  |

*Statistically significant at p<0.05
Table 2. Levels of CD4 count and hematological indices in the male and female HIV discordant test groups studied (mean±SD)

| Parameter               | Female control (n=20) | Male control (n=20) | Female discordant test group (n=20) | Male discordant test group (n=20) | f-value | P-value |
|-------------------------|-----------------------|---------------------|-------------------------------------|----------------------------------|---------|---------|
| Age (year)              | 30.5±4.5              | 40.7±4.6           | 37.5±5.6                           | 43.5±5.2                       | 25.128  | 0.000   |
| WBC (cells/µL)          | 5820.0±1821.97        | 5400.00±786.73     | 5790.00±1622.57                    | 5250.00±1414.77                | 0.753   | 0.524   |
| RBC (pg/L)              | 4.71±0.51             | 4.57±0.33          | 3.98±0.38                          | 4.23±0.65                      | 4.227   | 0.000   |
| HB (g/dl)               | 12.95±0.98            | 12.81±1.22         | 11.48±1.43                         | 12.37±1.97                     | 4.192   | 0.008   |
| HCT/PCV (%)             | 41.00±2.90            | 39.80±3.30         | 34.90±3.82                         | 35.98±9.40                     | 5.648   | 0.002   |
| Platelet (cells/µL)     | 280.20±60.41          | 275.70±53.34       | 261.70±75.97                       | 220.70±70.99                   | 3.392   | 0.022   |
| Lymphocyte (%)          | 52.00±1.86            | 52.30±4.23         | 44.85±11.16                        | 52.85±8.41                     | 4.189   | 0.008   |
| Neutrophil (%)          | 40.90±6.84            | 40.00±3.73         | 41.90±9.49                         | 34.50±8.66                     | 3.881   | 0.012   |
| CD4 (cells/mm³)         | 1042.95±109.86        | 1027.45±169.33     | 469.20±270.79                      | 763.75±360.55                  | 23.909  | 0.000   |

Key: a=compared with female control, b= compared with male control, c= compared with female test group

Table 3. Levels of CD4 and hematological indices in the participants studied (mean±SD)

| Parameter               | Female control (n=20) | Male control (n=20) | Female positives (n=16) | Female negatives (n=4) | Male positives (n=16) | Male negatives (n=4) | f-value | P-value |
|-------------------------|-----------------------|---------------------|-------------------------|-----------------------|-----------------------|----------------------|---------|---------|
| Age (year)              | 30.5±4.5              | 40.7±4.6           | 37.1±5.6               | 38.8±6.4                          | 45.3±7.5             | 43.1±4.6           | 15.054  | 0.000   |
| WBC (cells/µL)          | 5820.0±1821.97        | 5400.00±786.73     | 5168±1709.47            | 5275.00±1431.49            | 5087.50±1340.09      | 5145.00±1457.07      | 0.644   | 0.667   |
| RBC (pg/L)              | 4.71±0.51             | 4.57±0.33          | 3.99±0.24               | 3.95±0.79                  | 4.29±0.65            | 4.37±0.56            | 5.709   | 0.000   |
| HB (g/dl)               | 12.95±0.98            | 12.81±1.22         | 11.54±1.05              | 11.23±2.72                 | 12.43±1.98           | 12.40±1.53           | 2.523   | 0.037   |
| HCT/PCV (%)             | 41.00±2.90            | 39.80±3.30         | 34.88±3.28              | 35.00±6.22                 | 35.16±9.85           | 37.92±6.00           | 3.726   | 0.005   |
| Platelet (cells/µL)     | 280.20±60.41          | 275.70±53.34       | 263.88±78.03            | 253.00±77.36               | 225.63±67.35         | 259.5±86.78          | 2.101   | 0.075   |
| NUE/NAC (mixed cells (%)| 7.10±1.86            | 7.70±1.45          | 6.94±1.29               | 6.25±1.26                  | 6.50±1.03            | 7.03±1.48            | 1.631   | 0.163   |
| Lymphocyte (%)          | 52.00±1.86            | 52.30±4.23         | 44.69±12.31             | 45.50±5.45                 | 52.94±7.61           | 50.50±8.75           | 2.456   | 0.041   |
| Neutrophil (%)          | 40.90±6.84            | 40.00±3.73         | 42.31±10.40             | 40.25±4.92                 | 33.94±8.05           | 39.33±7.91           | 2.423   | 0.043   |
| CD4 (cells/mm³)         | 1042.95±109.86        | 1027.45±169.33     | 442.00±264.68            | 578.00±309.25              | 828.88±357.65        | 825.84±337.79        | 16.6672 | 0.000   |

Key: a=compared with female control, b= compared with male control, c= compared with female HIV positive
Furthermore, lower level of platelet count documented in the HIV serodiscordant couple in this study is an indication that these persons are at greater risk of thrombocytopenia.

This is in keeping with findings in previous studies involving HIV subjects [25,1] that observed varying levels of thrombocytopenia in HIV participants. However, increased platelet oxidation and inefficient platelet synthesis appear to be the mechanisms underlying thrombocytopenia in HIV infection. HIV-associated thrombocytopenia causes considerable platelet sequestration and destruction in the spleen.

Anemia, leucopenia, neutropenia, lymphopenia, and thrombocytopenia have been observed in HIV-infected people before or after ART initiation [17, 16], indicating that hematological abnormalities in HIV individuals are induced by either the virus or ART. More so, anemia, lymphocyte count, and thrombocytopenia are associated with CD4 levels [17].

Expectedly, this study found that the CD4+T-cell count was significantly lower in HIV serodiscordant participants compared to controls. This finding is in line with earlier studies [26, 27,28] that showed significantly decreased CD4 count in HIV participants compared to control. HIV infection primarily affects CD4 cells because of the virus’ affinity for CD4 cell surface receptors (CD4+).

An increase in susceptibility to a variety of opportunistic viral, bacterial, protozoal, and fungal infections as well as some malignancies results from the progressive impairment of cellular functions brought on by HIV infection, which is characterized by a gradual decline in peripheral blood CD4+ lymphocyte levels.

The results of this investigation demonstrated that there were no statistically significant differences between the discordant group and the control group in terms of mean WBC, lymphocyte, or neutrophil counts. This finding is consistent with that of Asemota et al. [29] that found no significant differences between control and HIV-naive patients and HIV-infected participants in terms of the mean WBC counts [29] but differs with some other reports [1]. This result may imply that in the participants in the study, gender differences do not significantly affect either the WBC or the mixed cells count (which includes monocyte, eosinophil, and basophil count).

There was significantly lower platelet count observed in the male HIV discordant test group when compared to the female control group. This demonstrates that male HIV-positive discordant couples may be more susceptible to thrombocytopenia than the general or healthy population. Thrombocytopenia has been reported in the literature among the HIV positive individuals previously [30] which agrees with the current results. Thrombocytopenia is the second most frequent complication of human immunodeficiency virus (HIV) infection with varied prevalence documented across the globe [31-35].

In this study, the mean level of RBC in the female HIV discordant test group was significantly lower than the levels observed in the female and male control groups, respectively. Additionally, compared to the female control group, the mean RBC level was significantly lower in the male HIV discordant test group. The mean HB level in the female HIV discordant test group was significantly lower than it was in the male and female control groups. When compared to the female and male control groups, the HCT/PCV level in the female HIV discordant test group was significantly lower. Additionally, the mean HCT/PCV level in the male HIV discordant test group was significantly lower than in the female control group. This research demonstrates that while men are similarly susceptible to anemia brought on by HIV infection and exposure, it affects women more severely. Impaired haematopoiesis, immune-mediated processes, opportunistic infections, lymphoma, and the myelotoxic effects of antiretroviral medications are some of the aetiologypathogenesis factors for anemia in HIV infection [35]. Anemia in HIV-positive people has been shown in several investigations as evidenced by significantly lower mean RBC, Hb, and PCV levels [36,1].
Furthermore, the mean lymphocyte counts were significantly higher in the male HIV discordant test group than in the female HIV discordant test group, but significantly lower in the female HIV discordant test group compared to the female and male control groups. In comparison to the female control group, the mean neutrophil counts in the male HIV discordant test group were significantly lower, but it did not differ significantly from those found in the female test group. This suggests that while the male discordant test group may be more susceptible to neutropenia than the female discordant group, the female discordant group may be more susceptible to lymphopenia. Numerous studies have recorded varying degrees of leucopenia characterized by lymphopenia and/or neutropenia [37] which corroborates with the present findings. Leucopenia and neutropenia have been linked to HIV infection in previous research [38, 39] while neutropenia makes HIV patients more vulnerable to bacterial infections, leucopenia is believed to increase the frequency of opportunistic infections [40]. According to reports, lymphopenia and a low lymphocyte total count are frequent symptoms of HIV infection [41,39].

Interestingly, the mean CD4 count was significantly lower in the male and female discordant test groups, respectively, than the values observed in the male and female control groups, while the mean CD4 count was significantly higher in the male discordant test group than in the female discordant test group. This result is consistent with past research [26-28].

The mean red blood cell count was significantly different between the groups and significantly lower in the female HIV seropositives than in the male and female control groups respectively. There was a significant difference between the groups’ mean hemoglobin (HB) levels as well. In comparison to controls, female HIV seropositives and exposed HIV seronegatives had significantly lower levels of hemoglobin (Hb). Furthermore, compared to female controls, PCV/HCT were significantly lower in female HIV-seropositives as well as exposed seronegative males. These results suggest that anemia caused by HIV infection and/or exposure affects both female HIV positives and HIV exposed seronegatives in a similar way. The fact that the current study identified partner HIV exposure as a risk factor that can result in anemia in such individuals is quite significant. Several studies have documented anemia in HIV infected individuals indicated by significantly lower mean levels of RBC, Hb and PCV [24,1]. The most prevalent hematologic abnormality among HIV-positive individuals is anemia, which is also linked to the course of the disease and a higher mortality risk for the patients [42]. Patients with HIV experience anemia for a variety of reasons. Hematopoietic stem/progenitor cells (HSPCs), which are found in the bone marrow, may be negatively affected by HIV both directly and indirectly [43, 44]. Additionally, the proliferation and differentiation of HSPCs during hematopoiesis may be impacted by ART medications, inflammatory mediators generated during HIV infection, coinfections, or opportunistic infections [43,44]. So, either the gradual depletion of HSPCs or the inhibition of their action may be the cause of anemia. In addition, a number of publications have noted that some ART combinations or monotherapy can cause anemia [45,46], which is consistent with the results of the current study. An important indicator that the anemia experienced by the HIV exposed seronegative participants in this study may be caused by their exposure to HIV infection in their partners is the fact that their HB, RBC, and PCV/HCT were significantly lower than in control subjects. As a result, it is important to monitor these indices in the exposed participants.

As anticipated, this study found that the CD4+T-cell count was significantly lower in the female HIV seropositives, female exposed HIV seronegatives, and male HIV seropositives as compared to the values seen in the male and female control groups. In comparison to female HIV positives, male HIV exposed seronegatives had a considerably lower mean CD4 count. As anticipated, this study found that the CD4+T-cell count was significantly lower in HIV-positive participants compared to controls. This finding is in line with earlier studies [26-28]. A progressive decrease in CD4+ T-cell populations, along with a steady decline in cellular immunity and an increase in vulnerability to opportunistic infections, is the defining feature of HIV infection and, subsequently, AIDS pathogenesis [47]. Furthermore, previous studies have shown no significant alterations in mean CD4 counts in HIV infected male and female participants [48]. This finding suggests that seronegative exposed partners also experience diminishing CD4+ T-cell counts as a result of HIV exposure, and as a result, continual depletion of these immune cells makes these people more susceptible to
infections that can worsen immunological function.

5. CONCLUSION

There was no statistically significant difference between the mean neutrophil, lymphocyte, or WBC counts in the HIV discordant test group and those in the control group. Female HIV discordant test subjects had statistically significantly lower HB, HCT/PCV, RBC, lymphocyte, and CD4 counts than female control subjects. Mean neutrophil and CD4 count differences between the male HIV discordant test group and the male control group were statistically significant. Female controls showed higher mean RBC counts, Hb counts, PCV counts, and CD4 counts than did female HIV-positives, all of which were statistically significantly lower. In addition, whereas the mean CD4 count and Hb levels of male HIV seropositives were statistically significantly lower than those of male controls, those of female HIV exposed seronegatives had lower mean CD4 counts and Hb levels. This finding calls for an urgent interventional strategy to prevent the potential anemia, leucocytopenia, and weakened immunity that may result in both HIV seropositives and seronegative exposed couples. Additionally, more research needs to be done with a larger sample size in order to confirm the findings of the current study.

CONSENT AND ETHICAL APPROVAL

Ethical approval was obtained from the Ethics Committees of the hospitals: Plateau State Specialist Hospital (PSSH/ADM/ETH.CO/2019/005); Faith Alive Foundation Hospital (FAFEC/08/34/25) and Our Lady of Apostles Hospital (dated 13th June, 2018) where the study was carried out. Informed consent of the participants were sought and obtained prior to the commencement of the study.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Aaron UU, Okonko IO, Frank-Peterside N. Haematological abnormalities among HIV positive patients on antiretroviral treatment in a Nigerian State, South of the Niger Delta. Biomedicine and Nursing. 2021; 7(3):1-7.
2. UNAIDS. Press Release; 2019. Available:https://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2019/march/20190314_nigeria]. Retrieved June on 29, 2022.
3. UNAIDS. Global HIV and AIDS statistics — Fact sheet; 2022. Available:https://www.unaids.org/en/resources/fact-sheet (Retrieved on 28 June, 2022).
4. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Abbastabar H, Abd-Allah F, Abdela J, Abdelalim A, x Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2022; 392(10159):1789–1858.
5. Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Abbastabar H, Abd-Allah F, Abdela J, Abdelalim A, Abdollahpour I, Abdulkader RS, Abebe HT, Abebe M, Abebe Z, Abejie AN, Aberra SF, Abil OZ, Abraha HN, Abrham AR & 30 others. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736–1788.
6. Awofala AA, Ogundele OE. HIV epidemiology in Nigeria. Saudi Journal of Biological Science. 2018;25(4):697-703.
7. UNFPA. World population dashboard Nigeria; 2020. Available:https://scholar.google.com/scholar_lookup?title=World%20population%20dashboard%20Nigeria&publication_year=2020 (Retrieved on June 29, 2022).
8. Mehra B, Bhalla P, Rawat D, Kishore J. A study of HIV-concordant and -discordant couples attending voluntary counselling and testing services at a tertiary care center in North India. Indian J Public Health. 2015;59:306–09.
9. Ravikumar B, Balakrishna P. Discordant HIV couple: Analysis of the possible contributing factors. Indian Journal of Dermatology. 2013;58(5):405.
10. Chemaitelly H, Cremin I, Shelton J, Hallett TB, Abu-Raddad LJ. Distinct HIV discordancy patterns by epidemic size in
stable sexual partnerships in sub-Saharan Africa. Sexually Transmitted Infections. 2012;88:51.
11. Curran K, Baeten JM, Coates TJ, Kurth A, Mugo NR, Celum C. HIV-1 prevention for HIV-1 serodiscordant couples. Current HIV/AIDS Reports. 2012;9(2):160-170.
12. Irungu EM, Heffron R, Mugo N, Ngure K, Katabira E, Bulya, N, Bukusi E, Odoyo J, Asiimwe, S, Tindimwebwa E, Celum C, Baeten JM, Partners Demonstration Project Team. Use of a risk scoring tool to identify higher-risk HIV-1 serodiscordant couples for an antiretroviral-based HIV-1 prevention intervention. BMC Infectious Disease. 2016;16(1):571.
13. Patel RC, Leddy AM, Odoyo J, Anand K, Stanford-Moore G, Wakhungu I, Bukusi EA, Baeten JM, Brown JM. What motivates serodiscordant couples to prevent HIV transmission within their relationships: Findings from a PrEP implementation study in Kenya. Culture, Health & Sexuality. 2018;20(6):625-639.
14. Balasubramaniam M, Pandhare J, Dash C. Immune control of HIV. Journal of Life Science (Westlake Village). 2019;1:4-37.
15. vanWoudenbergh E, Irvine EB, Davies L, de Kock M, Hanekom WA, Day CL, Fortune S, Alter G. HIV Is Associated with Modified Humoral Immune Responses in the Setting of HIV/TB Coinfection. mSphere. 2020;5(3):e00104-20.
16. Damtie S, Workineh L, Kiros T, Eyayu T, Tiruneh T. Hematological abnormalities of adult HIV-infected patients before and after initiation of highly active antiretroviral treatment at Debre Tabor Comprehensive Specialized Hospital, Northcentral Ethiopia: A cross-sectional study. HIV AIDS (Auckl). 2021;13:477-484.
17. Bhardwaj S, Almaeen A, Ahmed Wani F, Thirunavukkarasu A. Hematological derangements in HIV/AIDS patients and their relationship with the CD4 counts: a cross-sectional study. International Journal of Clinical and Experimental Pathology. 2020;13(4):756-763.
18. Tsukamoto T. Hematopoietic stem/progenitor cells and the pathogenesis of HIV/AIDS. Frontiers in Cellular and Infection Microbiology. 2020;10:60.
19. Okoroiwu HU, Okafor IM, Uko EK, Atangwho IJ. Some hematological parameters of Wistar rats treated with Chromolaenaodorata leave extracts.

Journal of Biological Research. 2017; 90(1):51–55.
20. Daniel WW. Biostatistics: a foundation for analysis in health sciences 7th edition, New York: John Wiley & Sons.
21. Duguma N, TesfaeyeKiya G, AdissuMaleko W, Bimerew LG. Hematological parameters abnormalities and associated factors in HIV-positive adults before and after highly active antiretroviral treatment in Goba Referral Hospital, southeast Ethiopia: A cross-sectional study. SAGE Open Medicine. 2021;9:20503121211020175.
22. Sasu DD. Labor force in Nigeria 2020, by age group; 2022. Available: https://www.statista.com/statistic/1203368/labor-force-in-nigeria-by-age/ (Retrieved on July 23, 2022)
23. Kerkhoff AD, Wood R, Cobelens FR, Gupta-Wright A, Bekker LG, Lawn SD. Resolution of anaemia in a cohort of HIV-infected patients with a high prevalence and incidence of tuberculosis receiving antiretroviral therapy in South Africa. BMC Infectious Diseases. 2014;14:3860.
24. Ositadinma IM, Odozi EB, Meludu SC, Okeke CO. Effects of HIV infection on some haematological parameters and immunoglobulin levels in HIV patients in Benin City, Southern Nigeria. Journal of HIV and Retrovirus. 2016;2(2):1-7.
25. Enawgaw B, Alem M, Addis Z, Melku M. Determination of hematological and immunological parameters among HIV positive patients taking highly active antiretroviral treatment and treatment naive in the antiretroviral therapy clinic of Gondar University Hospital, Gondar, Northwest Ethiopia: a comparative cross-sectional study. BMC Hematology. 2014;14(1):8.
26. Nsongu-Anyanya AC, Egbe ER, Agu CE, Ofors SJ, Usoro, CA, Essien IA. Nutritional indices and cardiovascular risk factors in HIV infection in Southern Nigeria. Journal of Immunology and Microbiology. 2017; 2(2):34–42.
27. Ezezugwunne IP, Ogboro EC, Analike RA, Okwara NA, Nnamdi JC, Iwuji JC, Obi-Ezeani, C.N, Amah AK, Odumodu IO, Onyenekwe CC. The pattern of alphafetoprotein, CD4+ count, albumin, AST, ALT and ALP in HIV subjects on long term antiretroviral therapy in Nauth Nnewi, Anambra State, Nigeria. Indian Journal of
28. Ezeugwunne IP, Ogbodo EC, Ezeuduji OO, Iwuji JC, Okwar MC, Obi-Ezeani CN, Amah AK, Odumodu IO, Iwuji JC, Okwara NA, Obi-Ezeani CN, Amah AK, Okafora IM, Okoroiwua HU, Ekonga ER, Anyanwua SO, Efiongb EE, Udomah F, Zinc, copper, CD4+ T-cell count and some hematological parameters in HIV-infected subjects in Southern Nigeria. Advances in Bioresearch. 2021; 4(3):199-205.

29. Asemota EA, Okafora IM, Amah AK, Odumodu IO, Iwuji JC, Okwara NA, Obi-Ezeani CN, Amah AK, Okafora IM, Okoroiwua HU, Ekonga ER, Anyanwua SO, Efiongb EE, Udomah F, Zinc, copper, CD4+ T-cell count and some hematological parameters in HIV-infected subjects in Southern Nigeria. Advances in Bioresearch. 2021; 4(3):199-205.

30. Abdulrahaman Y, Yeldu MH, Zama II, Amina A. Some Haematological Profile of HIV/AIDS Patients on Highly Active Antiretroviral Therapy (HAART) in UsmanuDanfodiyo University Teaching Hospital Sokoto, North Western Nigeria. American Journal of Science and Technology. 2014; 2(1):27-32.

31. Akinbami A, Oshinaike O, Adeyemo T, Adediran A, Dosunmu O, Dada M, Durojaie I, Adebola A, Vincent O. Hematologic abnormalities in treatment-naive HIV patients. Infectious Diseases: Research and Treatment. 2010; 3:45–49.

32. Butale P. Study of hematological profile in HIV-infected patients with correlation to CD4 cell count. International Journal of Medical Science and Diagnosis Research. 2019; 3(2):171-176.

33. Gebreweld A, Fiseha T, Girma N, Haileslasie H, Gebrehiwot D. Prevalence of cytopenia and its associated factors among HIV infected adults on highly active antiretroviral therapy at Mekel Meda Hospital, North Shewa Zone, Ethiopia. PloS One. 2020; 15(9):e0239215.

34. Patil SS, Patil VS. Correlation of blood profile and CD4 count in AIDS patients before and after HAART, Study in Western Maharashtra. Biomedical and Pharmacology Journal. 2020; 13(1):101–105.
Northwest Ethiopia. BMC Research Notes. 2019;12(1):168.

46. Kayode EM, Usiegbodi DO, Ajiboye ME, Omonye IS, Febut MN, Buru AS. Assessment of the effect of anti-retroviral therapy on haematological parameters in HIV positive individuals in Zaria. Journal of AIDS and HIV Research. 2020;12(2):17-23.

47. Okoye AA, Picker LJ. CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure. Immunological Reviews. 2013;254(1):54–64.

48. Ogbodo EC, Ezeugwunne IP, Ezeuduji OO, Analike RA, Okezie OA, Onuora IJ, Okwara EC, Nnamdi JC, Obi-Ezeani CN, Onyenekwe CC. Gender comparison of alpha-fetoprotein, CD4, albumin and some liver enzymes in symptomatic HIV subjects on antiretroviral therapy. Journal of Progressive Research in Biology. 2021;5(1):17-25.

© 2022 Duru et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/89768